Aranesp, Epogen Share In CKD, ESRD Will Remain Stable Despite Hemoglobin Targets – JP Morgan

After surveying nephrologists, JP Morgan analysts predict that use of the erythropoiesis-stimulating agents in kidney disease settings will not change dramatically.